Investing Profile

Frank Hensel

InvestorVC
Principal at HTGF | High-Tech Gründerfonds
Photo of Frank Hensel, Principal at HTGF | High-Tech Gründerfonds

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Hotmail Network
4901 CONNECTIONS
HTGF | High-Tech Gründerfonds Network
22 CONNECTIONS
HTGF | High-Tech Gründerfonds Network
22 CONNECTIONS
HTGF | High-Tech Gründerfonds Network
22 CONNECTIONS
cb
$100K - $5.0M
$1.5M
7
CompanyStageDateRound SizeTotal Raised
Computomics
Series AOct 2021
Co-investors: Markus Solibieda (BASF Venture Capital), Borris Foerster (Amathaon Capital)
Atriva Therapeutics
Debt FinancingAug 2020$10M
Series AJan 2019
SeedFeb 2017
$10M
Scipio Bioscience
Series AFeb 2020$7M
SeedNov 2017$1M
$8M
Co-investors: Philippe Tramoy (Seventure Partners)
Amal Therapeutics
Series AMar 2016$3M
$46M
Co-investors: Frank Kalkbrenner (Hotmail)
Post Doc University of WuerzburgPresent
Managing Director Patrys LimitedPresent
Investment Manager HTGF | High-Tech GründerfondsPresent
Board Observer ComputomicsPresent
Board Observer Amal TherapeuticsPresent
Board Member SciRhomPresent
Board Observer HepaRegeniX GmbHPresent
Board Observer Atriva Therapeutics GmbHPresent
Senior Investment Manager HTGF | High-Tech GründerfondsPresent
Board Observer Scipio BiosciencePresent
Board Member MecurisPresent
Principal HTGF | High-Tech GründerfondsPresent
Board Observer Alentis TherapeuticsPresent
Board Observer Abalos Therapeutics GmbHPresent
Board Observer DualyxPresent
Board Observer Tacalyx GmbHPresent
Board Observer Tubulis GmbHPresent
Board Member Tacalyx GmbHPresent
Founder & CEO HotmailPresent
Julius-Maximilians-Universität Würzburg Master's Degree Biophysics
Universität Osnabrück Master's Degree Biophysics
The Julius Maximilians University of Würzburg Doctor of Philosophy (Ph.D.) Analysis of the humoral immunity of stomach cancer patient with human monoclonal antibodies
Julius-Maximilians-Universität Würzburg Doctor of Philosophy (Ph.D.) Analysis of the humoral immunity of stomach cancer patient with human monoclonal antibodies